推荐产品
等級
pharmaceutical primary standard
API 家族
carvedilol
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
2-8°C
SMILES 字串
OC(COC1=CC=CC2=C1C3=C(C=CC=C3)N2)CNCCOC4=CC=CC=C4OC
InChI
1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3
InChI 密鑰
OGHNVEJMJSYVRP-UHFFFAOYSA-N
基因資訊
human ... ADRA1A(148) , ADRA1B(147) , ADRA1D(146) , ADRB1(153) , ADRB2(154) , ADRB3(155)
正在寻找类似产品? 访问 产品对比指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Carvedilol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化／生理作用
Cavedilol is a non-selective β-adrenergic blocker with α1 blocking activity. Carvedilol is used specifically for the treatment of heart failure and high blood pressure. It has been shown to improve left ventricular ejection fraction and may reduce mortality.
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
相關產品
产品编号
说明
价格
訊號詞
Warning
危險聲明
危險分類
Aquatic Chronic 2 - STOT RE 2
標靶器官
Liver,spleen,Uterus (including cervix),Adrenal gland
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Dhiraj Tripathi et al.
European journal of gastroenterology & hepatology, 22(8), 905-911 (2010-01-23)
Carvedilol is a potent noncardioselective beta-blocker, with weak vasodilating properties because of alpha 1 blockade. A reduction in both intrahepatic and portocollateral resistance contribute to enhanced effects on portal pressure. There are 10 published hemodynamic studies involving 168 patients investigating
Adrian J Stanley et al.
Journal of hepatology, 61(5), 1014-1019 (2014-06-24)
Rebleeding after an initial oesophageal variceal haemorrhage remains a significant problem despite therapy with band ligation, non-selective β-blockers or a combination of these. Carvedilol is a vasodilating non-selective β-blocker with alpha-1 receptor and calcium channel antagonism. A recent study has
Gonçalo C Pereira et al.
Current pharmaceutical design, 17(20), 2113-2129 (2011-07-02)
Mitochondria have long been involved in several cellular processes beyond its role in energy production. The importance of this organelle for cardiac tissue homeostasis has been greatly investigated and its impairment can lead to cell death and consequent organ failure.
James J DiNicolantonio et al.
The American journal of cardiology, 113(3), 565-569 (2013-12-18)
A systematic review and meta-analysis was performed to evaluate the effects of carvedilol versus metoprolol on the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting in randomized controlled trials. Ovid MEDLINE, PubMed, CENTRAL, and Excepta Medica
Carol Chen-Scarabelli et al.
American journal of cardiovascular drugs : drugs, devices, and other interventions, 12(6), 391-401 (2012-10-16)
β-Adrenergic receptor antagonists (β-blockers) have been recognized for their cardioprotective properties, prompting use of these pharmacologic agents to become more mainstream in acute myocardial infarction (AMI) and congestive heart failure (CHF). Despite their popularity as a class, the ability to
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门